Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial
<p>Introduction: We previously reported evidence that the T allele of the dopamine type-2 receptor (DRD2)rs1800497 polymorphism is associated with improved response to nicotine replacement therapy (NRT) relative to placebo and that this association may only be present in females. However, evid...
Principais autores: | Munafo, M, Johnstone, E, Murphy, M, Aveyard, P |
---|---|
Outros Autores: | Society for Research on Nicotine and Tobacco (SRNT) |
Formato: | Journal article |
Idioma: | English |
Publicado em: |
Oxford University Press
2009
|
Assuntos: |
Registros relacionados
-
Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial.
por: Munafò, MR, et al.
Publicado em: (2009) -
A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation.
por: Welton, N, et al.
Publicado em: (2008) -
Smoking cessation, weight gain, and DRD4 -521 genotype
por: Munafò, MR, et al.
Publicado em: (2006) -
Association between nicotinic acetylcholine receptor single nucleotide polymorphisms and smoking cessation.
por: Spruell, T, et al.
Publicado em: (2012) -
Lack of association of OPRM1 genotype and smoking cessation.
por: Munafò, MR, et al.
Publicado em: (2013)